Analysis of Irritable Bowel Syndrome Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
The global irritable bowel syndrome treatment market value was around US$ 2,744.9 million in 2019. Following the year 2019, several private players have surfaced with specialized and effective remedies for irritable bowel syndrome as well as inflammatory bowel disease.
The growing prevalence of irritable bowel syndrome (IBS) is the key factor driving the demand for IBS medication programs along with IBS natural remedies. In 2024, the net worth of revenue incurred from adopting irritable bowel syndrome treatment products and services is expected to be around US$ 4,076.1 million.
The need for efficient IBS therapy, as well as IBS counseling services, is expected to increase with the rising frequency of irritable bowel syndrome. According to the analysis of the market trends by Fact.MR, the demand for irritable bowel syndrome treatment is expected to progress at a CAGR of 8.7% between 2024 and 2034. By following this lucrative growth rate, the net valuation of the industry is expected to reach up to US$ 9,355.4 million by the end of 2034.
Irritable Bowel Syndrome Treatment Market Trends and Analysis
Personalized medicine and medical research advancements have significantly transformed the business model of treatment providers in the last few years. Customizing care to each patient's unique profile is currently an emerging trend, which has aided in improving both patient outcomes and treatment efficacy. Likewise, the introduction of a holistic approach to IBS is expected to fuel the demand for irritable bowel syndrome treatment services in the coming days.
The irritable bowel syndrome treatment industry outlook is evolving rapidly nowadays as a result of the increased use of telemedicine and mobile apps for the delivery of IBS therapy. To improve patient accessibility, providers use remote consultations and virtual therapies, especially when treating chronic diseases like IBS. So, the growing popularity of services like IBS virtual therapy and cognitive behavioral therapy for IBS is anticipated to boost the market demand further in the coming days.
| Report Attributes | Details |
|---|---|
| Estimated Market Value (2024E) | US$ 4,076.1 million |
| Forecasted Market Value (2034F) | US$ 9,355.4 million |
| Global Market Growth Rate (2024 to 2034) | 8.7% CAGR |
| Fiber Supplements Segment Growth Rate (2024 to 2034) | 9.6% CAGR |
| Irritable Bowel Syndrome with Diarrhea Segment Growth Rate (2024 to 2034) | 10.3% CAGR |
| Retail Pharmacies Segment Growth Rate (2024 to 2034) | 9.4% CAGR |
| North America Market Share (2024) | 8.8% |
| East Asia Market Share (2024) | 7.3% |
| Key Companies Profiled | Takeda Pharmaceutical Company Limited; Pfizer, Inc.; Abbott Laboratories; Novartis AG; AstraZeneca PLC; Ironwood Pharmaceuticals Inc. and Allergan Plc; Bausch Health Companies Inc.; GlaxoSmithKline, Plc.; Lexicon Pharmaceuticals, Inc.; Sucampo Pharmaceuticals, Inc. |
“IBS Trigger Foods and Hypnotherapy for IBS Treatment are the Emerging Trends”
Behavioral and psychological therapies for irritable bowel syndrome treatment have come a long way and are expected to improve further with a better understanding of the causes and symptoms of the disease.
It has prompted a higher recognition of the link between IBS and mental health, and medical professionals are prescribing stress management techniques and cognitive-behavioral therapy (CBT) more these days.
Recently, the involvement of the microbiota in irritable bowel syndrome was clarified by the research on the connection between gut microbiome and IBS. So, to enhance results, treatment providers use this information in their therapeutic techniques and offer a low FODMAP diet that focuses on gut microbiota balance.
| Country | Regional Market CAGR (2024 to 2034) |
|---|---|
| United States | 8.8% CAGR |
| South Korea | 7.9% CAGR |
“Surging Patients with Irritable Bowel Syndrome Driving the Market in China”
In Asia, demand for IBS management and treatment services has been brought on by patients' growing knowledge about the availability of professional help for managing and relieving IBS symptoms. In 2024, the net worth of all the irritable bowel syndrome treatment industries operating in the East Asian countries of China, Japan, and South Korea is estimated to be around US$ 542 million.
China, with a share of 63.5% of the East Asia market in 2024, emerged as a lucrative country for irritable bowel syndrome treatment products and service providers operating in the region. As the relationship between diet and IBS symptom relief is becoming widely acknowledged in the country, dietary strategies are increasingly emphasized in the treatment regimens.
According to the market estimates by Fact.MR, the net worth of total business, including IBS probiotic supplements, is expected to be around US$ 344 million in 2024. Meanwhile, South Korea is expected to witness a greater CAGR of 7.9%, and Japan is expected to follow China with a CAGR of 7.1% during this period.
“Greater Awareness of Patients and a Higher Demand for Personalized Treatment”
The market revenue generated in the North America irritable bowel syndrome (IBS) treatment market is estimated to be around US$ 1,722 million in 2024. Personalized IBS treatment solutions are driving the North American market as patient-centric care models are in higher demand in the United States and Canada.
The United States contributes nearly 89.2% of the North American market share, and the net valuation of this regional market is estimated to be around US$ 1,536 million in 2024. Market participants in the United States take into account the requirements, preferences, and lifestyle aspects of each patient, with an emphasis on a patient-centered and holistic approach.
For instance, Ardelyx, a biopharmaceutical company based in the United States, received approval for IBSRELA, a tenapanor medication used for the treatment of irritable bowel syndrome, in 2021.
The adoption of irritable bowel syndrome treatment services in Mexico is growing faster, and the regional market is anticipated to follow a CAGR of 8.9% through 2034, concluding at a valuation of US$ 92 million. On the other hand, the irritable bowel syndrome market in Canada is poised to witness a year-on-year growth rate of 8.7% and reach a valuation of 339 million by 2034.
“Fiber Supplements are Gaining More Traction than Lubiprostone and Antibiotics”
Among the different types of products available in the present market, lubiprostone is a sought-after treatment solution for irritable bowel syndrome patients. Currently, this segment captures around 22.4% of the total market share and is estimated to generate a revenue of around US$ 894.8 million in 2024. On the other hand, fiber supplements are observed to be growing at a faster rate as an effective treatment for irritable bowel syndrome diseases.
Leading market participants are now forming alliances with medical specialists that guarantee a comprehensive strategy that considers many facets of IBS treatment, including fiber supplements. Healthcare professionals also keep up with new supplement developments and incorporate them into thorough treatment plans. The fiber supplement segment is projected to increase with a CAGR of 9.6% between 2024 and 2034.
“Network of Retail Pharmacies Currently Contribute for One-Third of the Market Sales”
Based on the different distribution channels for irritable bowel syndrome treatment products, the retail pharmacies constitute the leading segment of the market. In 2024, the total revenue generated by this segment is expected to be nearly US$ 1,276.2 million.
With the advancement in pharmaceutical research, the development of new drugs for the treatment of IBS is expected to expand the share of retail distribution channels further. Over the next ten years, the retail pharmacies segment is predicted to expand at a CAGR of 9.4% to reach a valuation of US$ 3,123.8 million.
The global network of irritable bowel syndrome treatment service providers is gradually becoming competitive with the entry of players focused on other healthcare services earlier. In recent years, small-scale market players, particularly in emerging economies, have become prominent with the growing healthcare demands of people with irritable bowel syndrome.
Recent Developments by Irritable Bowel Syndrome Treatment Industry Participants
What was the Value of the Irritable Bowel Syndrome Treatment Market in 2019?
The irritable bowel syndrome treatment market was worth US$ 2,744.9 million in 2019.
What is the Sales Outlook for Irritable Bowel Syndrome Treatment in 2024?
The irritable bowel syndrome treatment market is likely to be valued at US$ 4,076.1 million in 2024.
What is the Demand Forecast for Irritable Bowel Syndrome Treatment for the Decade?
The irritable bowel syndrome treatment market value is likely to reach US$ 9,355.4 million by the end of 2034.
What is the Predicted Growth Rate for Irritable Bowel Syndrome Treatment Market?
Adoption of irritable bowel syndrome treatment is projected to rise at a CAGR of 8.7% through 2034.
At What Rate the United States Irritable Bowel Syndrome Treatment Market is Predicted to Grow?
The United States irritable bowel syndrome treatment market is likely to register a CAGR of 8.8% through 2034.
Irritable Bowel Syndrome Treatment Market